US tax credit agreement

Abingdon Health PLC

27 May 2026

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

US tax credit agreement

York, UK and Madison, WI, USA, 27 May 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that its US subsidiary, Abingdon Health USA, Inc., has entered into a Business Development Tax Credit Agreement with the Wisconsin Economic Development Corporation ("WEDC"). WEDC serves as the state's agency for economic development, fostering job growth and business expansion.

Under the agreement, Abingdon Health USA, Inc. has been certified as eligible to earn up to US$370,000 in performance-based Wisconsin tax credits over a three-year period commencing 1 January 2026. The credits comprise up to US$320,000 linked to the creation of new full-time roles and up to US$50,000 linked to qualifying capital investment at the Group's facilities in Wisconsin over this period.  The amount of credits the Company will receive is contingent on the number of jobs created and amount of capital invested.

This award reflects the continued growth of the Group's US operations and supports the ongoing expansion of its facilities in Madison, Wisconsin, which serve as Abingdon Health's North American base for development, manufacturing and commercial activities.

John W. Miller, Secretary and CEO of WEDC, said "Abingdon's decision to locate in Wisconsin and continue to grow here reflects the strength of our state's leadership in the field of biohealth and biotechnology, our outstanding research institutions, and our highly trained workforce.  WEDC is proud to partner with Abingdon as they open this next chapter."

Chris Yates, President of Abingdon Health USA Inc, said: "We are grateful for this award from the Wisconsin Economic Development Corporation, which serves as a welcome endorsement of our commitment and investment in Wisconsin and our positioning in the US market. These tax credits will support our expansion at University Research Park in Madison, including the creation of additional skilled roles as Abingdon Health USA continues to grow to meet customer demand across the United States."

Any shareholders wishing to keep up to date with Abingdon Health news, please email [e-mail]

Enquiries:

Abingdon Health plc	www.abingdonhealth.com/investors/
Chris Hand, Executive Chairman		Via Walbrook PR
Tom Hayes, CFO
Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)		Tel: [phone]
Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance) Nigel Birks (Life Science Specialist Sales)
Walbrook PR (Media & Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings	Mob: [phone]

About Abingdon Health

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.  

The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory strategy support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.  The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

Abingdon Health's brochures outlines the comprehensive support the Group can now provide to its international customers.  For more information visit: www.abingdonhealth.com.

LEI - 213800XFI4WV3FBILO20

 

END